Safety and efficacy
Micropulse TSCPC offers a kinder, gentler mechanism of action. Histopathologic studies demonstrate that its application does not coagulate or scar the treated region.4 We avoid this level of injury because we are not wiping out ciliary tissue, but rather inducing a change to the ciliary muscle in that region to lower IOP.
No cases of long-term hypotony were noted in treated eyes, a result that is shared by other investigators using the device.3,5 Since the tissue remains intact, even if the barrier breaks down more than intended, the effect is transient rather than a permanent structural change.
In addition to attacking the disease on the inflow front, there is evidence that IOP lowering is causal to a dual mechanism of decreased aqueous production and increased porosity producing uveoscleral outflow action.
With few disadvantages, micropulse TSCPC is an effective tool for improving our standard of care to glaucoma patients. Every patient is different, and we may not always achieve the desired result the first attempt, but the device affords the ability to repeat and customise treatment algorithms. While one technology does not help all, we can keep fighting.